Concurrent 6A: Abstract Session - Scaling Up Hepatitis C Treatment: What Works, What's Next
Tracks
Track 1
| Friday, October 17, 2025 |
| 11:45 AM - 1:15 PM |
Speaker
Dr. Aung Yu Naing
Health Director
Asian Harm Reduction Network
PREDICTORS OF SUSTAINED VIROLOGICAL RESPONSE IN HEPATITIS C TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS IN NORTHERN MYANMAR: AN ANALYSIS OF ROUTINE PROGRAM DATA
11:45 AM - 12:00 PMBiography
Health Director at AHRN, Australia Awards Scholar, holds an M.B;B.S and MIPH. Affiliated to research with Department of Global Public Health at Karolinska Institutet. With 18 years in Harm Reduction, he strategizes health interventions, develops programs, ensures quality medical interventions, specializing in HIV, TB, Hepatitis B, C, and drug treatment.
Ms Alison Boyle
Pharmacist
NHS GGC
THE MAJORITY OF PATIENTS WITH HEPATITIS C NOT ACHIEVING SVR CAN BE SUCCESSFULLY RETREATED WITH FIRST-LINE REGIMENS: RESULTS FROM A MULTIDISCIPLINARY TEAM APPROACH TO GUIDE TREATMENT DECISIONS
12:00 PM - 12:15 PMBiography
Alison Boyle is an Advanced BBV pharmacist in NHS Greater Glasgow and Clyde, Scotland. She has an MSc in Clinical Pharmacy and is a qualified independent prescriber. She also contributes to the content of the University of Liverpool drug interaction websites.
Dr. Jennifer Havens
Professor
University Of Kentucky
RE-ENGAGING RURAL RESIDENTS IN HCV TREATMENT AFTER SUBOPTIMAL OUTCOMES: ONE AND DONE IS NOT THE ANSWER
12:15 PM - 12:30 PMBiography
Dr. Havens is an ID epidemiologist whose research interests include characterizing the infectious complications of drug use in rural populations and HCV models of care in under-resourced Appalachian counties.
Mr Dylan Vella-Horne
Research Assistant
Burnet
Evaluating hepatitis C treatment engagement and completion among clients of a medically supervised injecting room in Melbourne, Australia
12:30 PM - 12:45 PMBiography
Dylan Vella-Horne is a Research Assistant at Burnet and a Public Health Master’s student. With over seven years of experience in supervised injecting facilities and supporting people who inject drugs, he specializes in blood-borne virus screening, treatment management, and harm reduction, with a strong focus on public health interventions.
Ms Joelle Dountio O.
Acting Director, HCV Program
Treatment Action Group
PREFERENCES AND FEASIBILITY OF LONG-ACTING TECHNOLOGIES FOR THE TREATMENT OF HEPATITIS C VIRUS: A SURVEY OF PATIENTS IN DIVERSE LOW-AND MIDDLE-INCOME COUNTRIES
12:45 PM - 12:50 PMBiography
Joelle Dountio is a Global Health Lawyer working to promote evidence-based health policy; and global health equity through timely access to safe and effective vaccines, diagnostics and medicines for prevention and treatment in low- and middle-income countries, and marginalized populations in high-income countries.
Dr Bidisha Kundu
Senior Research Associate In Mathematical Modelling Of Infectious Diseases
University Of Bristol
ESTIMATING THE IMPACT OF SCALING UP HEPATITIS C VIRUS TREATMENT AMONG PEOPLE WHO INJECT DRUGS IN TAYSIDE AND ALL OF SCOTLAND.
12:55 PM - 1:00 PMBiography
I am a mathematical modeler having experience in modeling in mechanical system, biomechanics, neuro-muscular system and infectious diseases.
Ms Siwaporn Niyomsri
Senior Research Associate
Bristol Medical School, University Of Bristol
ESTIMATING THE COST OF HEPATITIS C TREATMENT IN A RURAL APPALACHIAN COUNTY (KEY TREAT STUDY)
1:00 PM - 1:05 PMBiography
Siwaporn Niyomsri (Pharm.D., MSc) is a clinical pharmacist and health economist specializing in oncology and infectious diseases. Currently a Senior Research Associate at the University of Bristol. My work focuses on HCV, health economics, and policy research, particularly in LMICs and the UK.
Dr Martin Kåberg
Physician
Stockholm Centre for Dependency Disorders/Karolinska Institutet
TOWARDS HCV ELIMINATION AMONG PEOPLE WHO INJECT DRUGS IN SWEDEN
1:05 PM - 1:10 PMBiography
Senior Consultant of Psychiatry/Addiction Medicine/Infectious Diseases. Medical Suprevisor for the Stockholm Needle and Syringe Programs, PhD Karolinska Institutet, Department of Global Public Health. Major area of research is within harm reduction, people who inject drugs, HIV/hepatitis C and overdose prevention.
Ms Imen Farhat
PhD Student
McGill University
TRENDS IN HEPATITIS C CARE FOR PEOPLE WHO INJECT DRUGS IN QUEBEC, CANADA: PROVIDER SPECIALTY AND PATIENT CHARACTERISTICS
1:10 PM - 1:15 PMBiography
Imen Farhat, a PhD student in epidemiology, focuses on equitable access to healthcare, particularly primary care. Her research examines how health systems can improve accessibility for vulnerable populations. With expertise in health administrative data analysis, she aims to generate evidence that informs policy and supports decision-making.
Ms Rebekah Lamb
Project Manager
ASHM Health
ENHANCED SELF-EFFICACY IN HCV MANAGEMENT: EVALUATING THE OUTCOMES OF A MULTIDISCIPLINARY WORKFORCE EDUCATION PROGRAMME ACROSS FIVE AFRICAN COUNTRIES
1:15 PM - 1:20 PMBiography
Rebekah Lamb has a professional background in public health, communicable disease and sexual health, and has worked in this sector for 9 years. With extensive experience in project management and health promotion, both in Australia and internationally, Bek has held several roles coordinating community-based-blood-borne virus programs and developing education programs.
